Journal of Managed Care & Specialty Pharmacy

Article	Citations
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	44
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	36
What is needed to sustain comprehensive medication management? One health plan’s perspectives	36
Correction	30
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	23
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	19
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	19
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	18
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments	17
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	16
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	14
Associations between chronic active lesions and clinical outcomes in multiple sclerosis: A systematic literature review	14
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	14
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues	13
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	13
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	12
Real-world evidence: A new era is upon us	12
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	11
Trends in Medicaid spending on inhalers in the United States, 2012-2018	11
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	11
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	10
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	9
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	9
Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study	9
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	9

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	9
Real-world primary nonadherence to antiobesity medications	9
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	9
Poster Abstracts - Academy of Managed Care Pharmacy 2024	9
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	9
ICER report on Alzheimer’s disease: implications from a patient perspective	8
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	8
Association of dyskalemias with short-term health care utilization in patients with advanced CKD	8
The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective	8
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	8
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	8
Place of care and costs associated with acute episodes and remission in schizophrenia	8
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase–positive non–small cell lung cancer	8
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	7
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	7
Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs	7
AMCP Format for Formulary Submissions 5.0	7
Introducing the Managed Care Pharmacy Primer Series	7
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study	7
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States	7
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population	7
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	7
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer	7
Evolution of the Military Health System compounded drugs utilization and management	7
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	6
First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eli	6
When are breakthrough therapies cost-effective?	6
A dynamic analysis of medication adherence	6
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs	6
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States	6
Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States	6
Addressing gaps to strengthen patient-centricity in formulary decision-making: An example applied to Colorado’s prescription drug affordability board implementation	6
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	6
Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review	6
Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis	6
Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act	6
Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States	6
From access to equity: The devil is in “Z” details	6
The patient’s medication access journey: a conceptual framework focused beyond adherence	6
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia	6
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	6
Cost sharing in managed care and the ethical question of business purpose	6
Resmetirom for nonalcoholic steatohepatitis	6
Correction	6
AMCP Partnership Forum: Biosimilars—policy, practice, and postmarketing surveillance to support treatment and coverage decisions	5
Poster Abstracts - Academy of Managed Care Pharmacy 2025	5
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	5
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	5
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	5
Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives	5

Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program	5
The economic burden of Parkinson disease among Medicare beneficiaries	5
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program	5
Risk of asthma exacerbation associated with opioid and nonopioid analgesic use in children with current asthma	5
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement	5
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	5
AMCP Partnership Forum: Racial health disparities—a closer look at benefit design	5
Correction	5
AMCP Market Insights: Payer best practices in food allergy management	5
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	5
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review	5
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma	5
Payer perceptions on the use of patient-reported outcomes in oncology decision making	5
Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy	5
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	5
AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care	5
Cost per outcome of nivolumab + relatlimab vs BRAF + MEK inhibitor combinations for first-line treatment of BRAF-mutant advanced melanoma	4
Building health plan–pharmacist provider partnerships to optimize medication outcomes	4
A primer on copay accumulators, copay maximizers, and alternative funding programs	4
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	4
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	4
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	4
Limited utility of price transparency data for drugs	4
Advancing the conversation: 30 years of scholarship in managed care pharmacy	4
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	4
Characterizing health plan evidence review practices	4
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	4
Burden of hospitalization for heart failure in the United States: a systematic literature review	4
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	4
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	4
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	4
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	4
Atidarsagene autotemcel for metachromatic leukodystrophy	4
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	4
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	4
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	4
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	4
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	4
Health care resource utilization and costs among patients with spasticity or cervical dystonia	4
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States	4
Health care costs and resource utilization among patients with myasthenia gravis in the United States	4
Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste	4
The effectiveness and value of aducanumab for Alzheimer’s disease	4
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	4
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	4
Corrections	4
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	4
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	4
Oral treatments for outpatient COVID-19: Effectiveness and value	4
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	4
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria	4
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review	4
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder	3
Pharmacist vs physician management of e-visit requests for COVID-19 medication: A randomized clinical trial	3
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States	3
Marginal health care expenditures for melanoma care in the United States	3
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	3
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste	3
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	3
Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data	3
HIV preexposure prophylaxis treatment patterns in a national health plan population	3
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	3
Emerging trends in pharmacy operations: Perspectives on the 2024 AMCP Foundation Survey	3
Validation of EHR medication fill data obtained through electronic linkage with pharmacies	3
Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims	3
Will the emerging private-label market access channel help or hinder biosimilar market access?	3
AMCP Market Insights: Payer best practices for timely diagnosis and optimal management of idiopathic hypersomnia	3
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018	3
Cost-related barriers to medication use among diverse participants with obesity-associated asthma	3
Procurement and use of social determinants of health data among key health care stakeholders	3
Marginal health care expenditures and health-related quality of life burden in patients with migraine	3
The impact of biosimilar insulins on the diabetes landscape	3
The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council	3
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States	3
Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis	3
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes	3
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable	3
Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi	3
Does the diabetes health plan have a differential impact on medication adherence among beneficiaries with fewer financial resources?	3
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States	3

Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	3
The impact of opioid prescribing report cards in Medicaid	3
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	3
Evolving oncology care management trends in the United States: A survey among health care decision makers	3
Pharmacoequity measurement framework: A tool to reduce health disparities	3
Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs	3
Poster Abstracts - Academy of Managed Care Pharmacy 2022	3
Addressing complexity: The development and pilot testing of a user-friendly Medicare Part D patient decision aid tool	3
Use of prescriber requirements among US commercial health plans	3
Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care	3
The time is now: Addressing health inequities in the workforce	3
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	3
Telephone-based social health screening by pharmacists in the nonadherent Medicare population	3
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension	3
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C	3
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States	3
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema	3
Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease	3
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cance	3
Correction	3
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	3
Pharmacist-managed multistep order transmittal for electronic specialty prescriptions reduces represcribing burden in ambulatory clinics: A retrospective cohort pilot study	3
The effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa	3
Formulary tiers, medication cost sharing, and transparency in bronze and silver qualified health plans in 2014 vs 2018	3
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	3
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	3